Thursday, June 26, 2008

Alkermes brings opioid dependence treatment into Phase 3

By Mass High Tech Staff


Cambridge biotech firm Alkermes Inc. has begun a Phase 3 clinical trial of its Vivitrol long-term treatment for opioid dependence, the company reports.

Using 200 opioid-dependent patients, the clinical study will test the safety of the treatment for the chronic brain disease, with the goal of filling out a supplemental New Drug Application for the U.S. Food and Drug Administration.

Vivitrol got FDA approval in April 2006 as a treatment for alcohol dependence.

Elliot Ehrich, Alkerme’s chief medical officer, called it the only non-addictive, non-narcotic and long-lasting opioid dependency treatment.

Alkermes reported net income of $9.5 million for 2007 on revenue of $239.97 million. The firm produces treatments for alcohol dependence and schizophrenia.



 

Contact Editor Latest News    

Comments

Please Login/Register to post comments.

No comments have been added or approved.

Use of, registration on, this site constitutes acceptance of our User Agreement. Please read our Privacy Policy (updated) A publishing partner with Portfolio